Table 1.
Associations between EPIC1 expression level and baseline clinicopathological characteristics.
| Characteristics | EPIC1 low (n = 27) | EPIC1 high (n = 84) | p value |
|---|---|---|---|
| Age (years) | 0.299 | ||
| ⩾50 | 14 (51.9%) | 53 (63.1%) | |
| <50 | 13 (48.1%) | 31 (36.9%) | |
| Median (range) | 50 (26–70) | 53 (31–69) | |
| Menopausal status | 0.207 | ||
| Premenopausal | 15 (55.6%) | 35 (41.7%) | |
| Postmenopausal | 12 (44.4%) | 49 (58.3%) | |
| T stage | 0.792 | ||
| T2 | 6 (22.2%) | 14 (16.7%) | |
| T3 | 13 (48.2%) | 45 (53.5%) | |
| T4 | 8 (29.6%) | 25 (29.8%) | |
| N stage | 0.268 | ||
| N0 | 1 (3.7%) | 9 (10.7%) | |
| N1–N3 | 26 (96.3%) | 75 (89.3%) | |
| ER status | 0.381 | ||
| ER positive | 18 (66.7%) | 48 (57.1%) | |
| ER negative | 9 (33.3%) | 36 (42.9%) | |
| PR status | 0.822 | ||
| PR positive | 18 (66.7%) | 54 (64.3%) | |
| PR negative | 9 (33.3%) | 30 (35.7%) | |
| HER2 status | 0.001 | ||
| HER2 positive | 4 (14.8%) | 42 (50.0%) | |
| HER2 negative | 23 (85.2%) | 42 (50.0%) | |
| Ki67 index | 0.226 | ||
| ⩾20% | 24 (88.9%) | 78 (92.9%) | |
| <20% | 3 (11.1%) | 6 (7.1%) | |
| Histologic grade | 0.034 | ||
| G2 | 13 (48.1%) | 21 (25.0%) | |
| G3 | 14 (51.9%) | 55 (65.5) | |
| Unevaluable | 0 (0%) | 8 (9.5%) | |
| Molecular subtype | 0.149 | ||
| Luminal-A like | 3 (11.1%) | 3 (3.6%) | |
| Luminal-B like | 17 (63.0%) | 58 (69.0%) | |
| HER2 positive | 1 (3.7%) | 12 (14.3%) | |
| Basal like | 6 (22.2%) | 11 (13.1%) |
The p values are calculated using the chi-squared test.
ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; N stage, nodal stage; PR, progesterone receptor; T stage, tumor stage.